ARMO BioSciences Adds $67M For Cancer Treatments
Redwood City-based ARMO Biosciences, a developer of cancer treatments, said today that it has raised $67 in a Series C-1 funding. The funding was led by Qiming Venture Partners, and also included Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments plus Kleiner Perkins (KP), OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments, GV (formerly Google Ventures), Celgene Corporation, and certain private investment funds advised by Clough Capital Partners L.P. The company said the funding goes towards Phase 2/3 studies on its lead compound, aimed at treating non-small cell lung cancer and renal cell cancer and to support an ongoing pivotal phase 3 clinical trial in advanced pancreatic cancer.
posted on Tuesday, August 29, 2017 (Link to more information)
Related companies:
Armo Biosciences
Related stories:
> ARMO BioSciences Files For IPO
> ARMO BioSciences Takes $50M
> Calithera Biosciences Raises $40M
> IDEAYA Biosciences Gets $94M In Series B For Oncology Efforts
> 3-V Biosciences Finds $20M In Funding
silicontap.com Home